Sökning: onr:"swepub:oai:DiVA.org:uu-343671" >
KRAS and BRAF mutat...
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
-
- Sclafani, Francesco (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Chau, Ian (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Cunningham, David (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
visa fler...
-
- Hahne, Jens C. (författare)
- Inst Canc Res, London, England.;Inst Canc Res, Surrey, England.
-
- Vlachogiannis, George (författare)
- Inst Canc Res, London, England.;Inst Canc Res, Surrey, England.
-
- Eltahir, Zakaria (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Lampis, Andrea (författare)
- Inst Canc Res, London, England.;Inst Canc Res, Surrey, England.
-
- Braconi, Chiara (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.;Inst Canc Res, London, England.;Inst Canc Res, Surrey, England.
-
- Kalaitzaki, Eleftheria (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- De Castro, David Gonzalez (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Wotherspoon, Andrew (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Capdevila, Jaume (författare)
- Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona, Spain.
-
- Glimelius, Bengt (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Tarazona, Noelia (författare)
- Univ Valencia, Biomed Res Inst INCLIVA, Valencia, Spain.
-
- Begum, Ruwaida (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Lote, Hazel (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.;Inst Canc Res, London, England.;Inst Canc Res, Surrey, England.
-
- Wilson, Sanna Hulkki (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Mentrasti, Giulia (författare)
- Inst Canc Res, London, England.;Inst Canc Res, Surrey, England.
-
- Brown, Gina (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Tait, Diana (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Oates, Jacqueline (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.
-
- Valeri, Nicola (författare)
- Royal Marsden NHS Fdn Trust, London, England.;Royal Marsden NHS Fdn Trust, Surrey, England.;Inst Canc Res, London, England.;Inst Canc Res, Surrey, England.
-
visa färre...
-
Royal Marsden NHS Fdn Trust, London, England;Royal Marsden NHS Fdn Trust, Surrey, England. Inst Canc Res, London, England.;Inst Canc Res, Surrey, England. (creator_code:org_t)
- 2018-01-23
- 2018
- Engelska.
-
Ingår i: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 8
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- There are limited data on circulating, cell-free, tumour (ct) DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd) PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX +/- cetuximab in a randomised phase II trial. KRAS mutation in G12D, G12V or G13D was detected in the ctDNA of 43% and 35% of patients with tumours that were mutant and wild-type for these hotspot mutations, respectively, according to standard PCR-based analyses on tissue. The detection rate in the ctDNA of 10 patients with less common mutations was 50%. In 26 cases ctDNA analysis revealed KRAS mutations that were not previously found in tissue. Twenty-two of these (84.6%) were detected following repeat tissue testing by ddPCR. Overall, the ctDNA detection rate in the KRAS mutant population was 66%. Detection of KRAS mutation in ctDNA failed to predict prognosis or refine patient selection for cetuximab. While this study confirms the feasibility of ctDNA analysis in LARC and the high sensitivity of ddPCR, larger series are needed to better address the role of ctDNA as a prognostic or predictive tool in this setting.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sclafani, France ...
-
Chau, Ian
-
Cunningham, Davi ...
-
Hahne, Jens C.
-
Vlachogiannis, G ...
-
Eltahir, Zakaria
-
visa fler...
-
Lampis, Andrea
-
Braconi, Chiara
-
Kalaitzaki, Elef ...
-
De Castro, David ...
-
Wotherspoon, And ...
-
Capdevila, Jaume
-
Glimelius, Bengt
-
Tarazona, Noelia
-
Begum, Ruwaida
-
Lote, Hazel
-
Wilson, Sanna Hu ...
-
Mentrasti, Giuli ...
-
Brown, Gina
-
Tait, Diana
-
Oates, Jacquelin ...
-
Valeri, Nicola
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Scientific Repor ...
- Av lärosätet
-
Uppsala universitet